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Mesenchymal stem cells (MSC) are under investigation as a therapy for a variety of
disorders. Although animal models show long term regenerative and immunomodulatory
effects of MSC, the fate of MSC after infusion remains to be elucidated. In the present
study the localization and viability of MSC was examined by isolation and re-culture
of intravenously infused MSC. C57BL/6 MSC (500,000) constitutively expressing
DsRed-fluorescent protein and radioactively labeled with Cr-51 were infused via the tail
vein in wild-type C57BL/6 mice. After 5min, 1, 24, or 72 h, mice were sacrificed and blood,
lungs, liver, spleen, kidneys, and bone marrow removed. One hour after MSC infusion the
majority of Cr-51 was found in the lungs, whereas after 24 h Cr-51 was mainly found in the
liver. Tissue cultures demonstrated that viable donor MSC were present in the lungs up to
24h after infusion, after which they disappeared. No viable MSC were found in the other
organs examined at any time. The induction of ischemia-reperfusion injury in the liver did
not trigger the migration of viable MSC to the liver. These results demonstrate that MSC
are short-lived after i.v. infusion and that viable MSC do not pass the lungs. Cell debris
may be transported to the liver. Long term immunomodulatory and regenerative effects of
infused MSC must therefore be mediated via other cell types.
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INTRODUCTION
Mesenchymal stem cells (MSC) are considered as a potential
therapy for a wide variety of degenerating and immunological
disorders (Giordano et al., 2007; Reinders et al., 2010; Salem
and Thiemermann, 2010). Animal models demonstrate that MSC
induce the repair of injured organs and ameliorate inflammatory
processes (Morigi et al., 2008; Aurich et al., 2009; Gonzalez-Rey
et al., 2009; Fisher-Shoval et al., 2012). The encouraging results
in such models have initiated the translation of MSC therapy in
clinical trials in a range of disorders, including graft versus host
disease, inflammatory bowel disease, and cardiac infarct (Le Blanc
et al., 2008; Hare et al., 2009; Duijvestein et al., 2010). Trials in
multiple sclerosis (Freedman et al., 2010), systemic lupus erythe-
matosus (Liang et al., 2010), and in organ transplantation (Perico
et al., 2011; Popp et al., 2011; Tan et al., 2012) are currently
ongoing or in preparation.
A problem with the interpretation of results and optimization
of trials with MSC is a lack of understanding of the mechanism
of action of MSC. While MSC have the capacity to differenti-
ate into multiple cell types (Pittenger et al., 1999; Long et al.,
2005), secrete growth factors that stimulate the proliferation and
differentiation of other cells (Lee et al., 2011), and inhibit the
proliferation of immune cells in vitro via the secretion of anti-
inflammatory factors (Di Nicola et al., 2002), it is unknown
whether these mechanisms are operational after administration
of MSC. Moreover, there is controversy about the localization
and persistence of MSC in the body after administration. The
route of administration is an important factor determining the
fate of MSC. The favorite route of administration in human is
intravenously, as this has proven to be safe and allows the admin-
istration of large amounts of MSC. Tracking studies have shown
that the majority of MSC localize to the lungs after intravenous
infusion (Barbash et al., 2003; Kraitchman et al., 2005; Fischer
et al., 2009; Assis et al., 2010). The detainment of MSC in the
lungs is due to space restriction, as cultured MSC are more than
20μm in diameter (Crop et al., 2010) and therefore much larger
than circulating immune cells and larger than the width of the
micro-capillaries of the lungs. Administration ofMSC via alterna-
tive routes leads to detainment of MSC in other filtering organs.
For instance, MSC administered via the portal vein are found in
the liver (Shi et al., 2010), while MSC administered in tissues like
muscle, spine, and fat pads remain present locally up to several
weeks (Boulland et al., 2012; Hu et al., 2012; Nam et al., 2012).
After intravenous administration, MSC tend to disappear from
the lungs within hours and migrate to other tissues such as the
spleen and liver (Devine et al., 2003; Kraitchman et al., 2005) and
preferentially to sites of injury (Chapel et al., 2003; Assis et al.,
2010; Jackson et al., 2010; Jin et al., 2012). However, care should
be taken with interpreting these results. Studies examining the
distribution of MSC after intravenous infusion rely on PCR tech-
niques, immunofluorescence, or bioluminescence to detect DNA,
fluorescence label, or luciferase enzyme activity from infused
MSC, but do not encompass the detection of living MSC. It is not
unlikely that label is detected in deadMSC or inmacrophages that
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have phagocytosed MSC. Detection of label provides therefore no
information on the localization and persistence of living MSC.
Many studies examining the distribution of MSC use (severely)
immuno-compromised recipient animals (Pereira et al., 1995;
Liechty et al., 2000; Devine et al., 2003; Boulland et al., 2012). In
most human studies, MSC recipients will have a more functional
immune system and this is likely to affect the survival of MSC.
The idea that MSC may not survive long after administration is
supported by evidence demonstrating that the majority of MSC
become apoptotic after administration (Liu et al., 2012).
In the present study we examined the localization of liv-
ing MSC after intravenous infusion in immunocompetent mice
by re-establishing cultures of administered MSC. Bone marrow-
derived MSC of C57BL/6 mice that constitutively express DsRed
were infused via the tail vein of wild-type C57BL/6 mice. After
5min, 1, 24, or 72 h blood was taken and lung, spleen, liver,
kidney, and bone marrow removed, MSC isolated and brought
into culture. After 1 week of culture, the presence of adherent
DsRed-MSC was analyzed by microscopy and flow cytometry.
The outcome was compared to the results obtained from distri-
bution experiments with radioactive labeled MSC in the same
model.
MATERIALS ANDMETHODS
ETHICS STATEMENT
All animal experiments were carried out in accordance with
European communities council directive (86/609/EEC) and insti-
tutional guidelines for animal care after local ethics commit-
tee approval (Ethics committee for animal laboratories, Medical
Faculty, University of Regensburg, 93042, Regensburg, Germany).
The MSC tracking studies were conducted after approval by the
local authorities governing health care (Regierung der Oberpfalz,
Emmeransplatz 8, 93047, Regensburg, Germany, www.ropf.de;
AZ: 54-2532.1-33/08).
EXPERIMENTAL ANIMALS
We used DsRed C57BL/6 mice (Jax, stock number 006051; http://
www.jaxmice.jax.org) as MSC donors. These transgenic mice,
which carry an Actb-DsRed.T3 transgene, express the red flu-
orescent protein variant DsRed.MST under the control of the
chicken beta actin promoter coupled with the cytomegalovirus
(CMV) immediate early enhancer. All tissues of homozygotes are
red fluorescent. 6–8-weeks-old wild-type C57BL/6 mice (Charles
River Laboratories, Sulzfeld, Germany) were used as MSC recip-
ients. For some experiments, Rag2−/− × common cytokine
receptor γ-chain−/− double knock out (Rag2−/− × γ-chain−/−)
mice lacking T, B, and NK cells were used as MSC recipients.
Laboratory animals were housed with access to food and water
provided ad libitum. Water was provided via standard lab water
bottles which were replenished daily. Cages were cleaned weekly.
All veterinary procedures were performed only with sedated
animals. All efforts were taken to ameliorate any suffering.
Liver ischemia-reperfusion injury was induced according to
Abe et al. (2009). In brief, ischemia-reperfusion injury was
induced by placing an atraumatic clip across the portal vein, hep-
atic artery, and bile duct just above the branching to the right
lateral lobe. The median and lateral lobe (approximately 70% of
the liver) showed significant blanching. After 45min of ischemia,
the clamp was removed and the liver reperfused.
ISOLATION AND CULTURE OF MSC
MSC were isolated from tibias and femurs of DsRed C57BL/6
mice by flushing. The obtained cell suspension was washed and
plated in tissue culture flasks in MEM alpha supplemented with
10% heat-inactivated fetal calf serum (FCS), and 100U/mL peni-
cillin and 100mg/mL streptomycin (1% p/s) (all Invitrogen,
Karlsruhe, Germany). After 2–3 days non-adherent cells were
removed. Plastic adherent cells were removed by trypsiniza-
tion after reaching 70–80% confluency. After the first pas-
sage, CD11b+ cells were depleted from the cultures by MACS
(Miltenyi, Bergisch Gladbach, Germany). Cells were maintained
at 37◦C, 5% CO2, and 95% humidity, culture medium refreshed
twice weekly and used for experiments between passage 2 and 5.
CHARACTERIZATION OF DsRed-MSC
DsRed-MSC were examined for DsRed expression by fluores-
cence microscopy and flow cytometry using a FACS Calibur
(BD Biosciences, San Jose, USA). For surface marker charac-
terization, MSC were harvested and washed twice in ice-cold
phosphate-buffered saline (PBS). Stainings were performed in
50μl of pre-diluted FITC-conjugated anti-mouse CD34, CD11b,
Sca-1 orMHC-I, and APC-conjugated anti-mouse CD44, CD11c,
or CD117 antibody (all from BD Biosciences, Heidelberg,
Germany). After 20min incubation at 4◦C in the dark, 400μl of
PBS was added, and the cells analyzed with the FACS Calibur flow
cytometer.
Differentiation of MSC into adipocytes was achieved by
plating MSC into six-well plates in expansion medium with-
out FCS for 2 days. Differentiation was induced by cultur-
ing the cells in expansion medium without FCS supplemented
with insulin (15U/ml; Sanofi-aventis, Paris, France), dexam-
ethasone (10−6 M; Sigma-Aldrich, St. Louis, USA), goat serum
(5ml/100ml; PromoCell, Heidelberg, Germany), and 3-isobutyl-
1-methylxanthin (0.1mg/ml; Sigma-Aldrich) for 3 days. The cells
were then cultured in expansion medium without FCS supple-
mented with insulin (15U/ml; Sanovi-aventis) for 5 days. Cell
differentiation into adipocytes was confirmed by oil red O stain-
ing. Cells were washed in cold PBS, fixed with 10% formaldehyde
at 4◦C for 10min, and then incubated with 5mg/ml oil red O
solution (Sigma-Aldrich, Munchen, Germany) for 2 h at room
temperature.
To induce osteogenic differentiation, MSC were seeded in six-
well plates at a density of 15,000 cells per cm2 in DMEM without
FCS for 1 day. Cells were then treated with osteogenic medium
for two weeks, changing the medium twice a week. Osteogenic
medium consisted of DMEM supplemented with 0.1μM dexam-
ethasone, 0.3mM ascorbic acid, and 10mM α-glycerolphosphate
(all Sigma-Aldrich). Osteogenic differentiation was assessed by
von Kossa staining. Cells were covered with 5% silver nitrate solu-
tion for 40min in bright light followed by an incubation step in
UV light for 2min. After rinsing with distilled water, cells were
incubated for 5min in 1% pyrogallol (Sigma-Aldrich) and rinsed
again. Non-specific staining was removed by washing the cells in
5% sodium thiosulfate (Sigma-Aldrich) for 5min.
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For examination of the immunomodulatory capacity of
DsRed-MSC, splenocytes of C57Bl/6, or Balb/c mice were labeled
with CFSE (Vybrant Cell Tracer Kit, Molecular Probes, Eugene,
Oregon, USA) and stimulated with 2 ng/ml Concanavalin A
(ConA) in MEM alpha with 10% FCS and 1% p/s. DsRed-MSC
were added at a 1:5 ratio. After 3 days, splenocytes were collected,
stained for CD3 and CD4 (BD Biosciences), and analyzed on the
flow cytometer.
INFUSION OF DsRed-MSC
DsRed-MSC were trypsinized and washed twice with PBS. A sus-
pension of 500,000 DsRed-MSC in PBS was infused via the tail
vein of C57BL/6 mice or Rag2−/− × γ-chain−/− mice. Control
animals received PBS only. Mice were sacrificed after 5min, 1, 24,
or 72 h, blood collected, and lungs, liver, spleen, kidneys, and
bone marrow removed.
ORGAN HARVEST AND RE-ISOLATION OF DsRed-MSC
Blood
Approximately 1ml blood was collected and red blood cells lysed
in red cell removal buffer (Roche, Germany). The cells were then
washed and plated out in tissue culture flasks in MEM alpha with
10% FCS and 1% p/s.
Lungs, kidneys, spleen
Organs were minced with a scalpel knife and incubated in
0.5mg/ml collagenase in PBS for 30min in a shaker at 37◦C.
The tissue was then put several times through a 19G needle with
a syringe, washed, taken up in MEM alpha with 10% FCS and
1% p/s, filtered through a 100μm cell strainer, and plated out in
tissue culture flasks.
Liver
Livers were harvested and prepared with the Gentle MACS dis-
sociator according to the protocol (Miltenyi, Bergisch Gladbach,
Germany) without the final centrifugation step to obtain a single
cell suspension including all liver cells. Cells were washed, taken
up in MEM alpha with 10% FCS and 1% p/s, and plated out in
tissue culture flasks.
Bone marrow
Tibias and femurs were flushed with PBS and the cell suspension
was washed and plated out in tissue culture flasks in MEM alpha
with 10% FCS and 1% p/s.
After 2 and 7 days of culture, non-adherent cells were removed
by washing and the adherent cells examined for the presence of
DsRed-MSC by fluorescence microscopy.
INFUSION OF RADIO-LABELED DsRed-MSC
DsRed-MSC were radio-labeled using a protocol described by
Sprent (1976). Briefly, MSC were diluted to a concentration
of 20 × 106 /ml and incubated with 20μCi/ml Cr-51 Sodium
(PerkinElmer, Waltham, MA, USA) for 1 h followed by two
washes with medium. Subsequently, 500,000 radio-labeled cells
were infused via the tail vein of C57BL/6 mice. The animals were
sacrificed and blood and organs removed after 1 or 24 h. Organs
were place in vials and radioactivity measured as counts/min with
a 1470 Wallac Wizard gamma counter (PerkinElmer).
RESULTS
CHARACTERIZATION OF DsRed-MSC
DsRed-MSC isolated from the bone marrow had a typical
fibroblast-like appearance in culture, similar to wild-type MSC
(Figure 1A). They expressed the MSC markers Sca-1 and CD44,
and were negative for CD34, CD11b, CD11c, and CD117. They
had only a weak expression of MHC class I, and constitutively
expressed high levels of DsRed (Figure 1B).
To show that DsRed-MSC are able to differentiate like wild-
type MSC, we cultivated them under adipogenic and osteogenic
conditions. After 2 weeks in culture, DsRed-MSC started to dif-
ferentiate into adipocytes, as demonstrated by positive oil red
O staining of lipid-filled vesicles (Figure 1C, left). Importantly,
these differentiated cells still remained red fluorescent (Figure 1C,
right). After 2 weeks in osteogenic differentiation medium,
DsRed-MSC started to deposit calcified nodules, which stained
black with silver nitrate (Figure 1D, left). Also, the differentiated
osteoblasts remained red fluorescent (Figure 1D, right).
DsRed-MSC furthermore shared the property of wild-type
MSC of inhibiting the proliferation of ConA stimulated spleno-
cyte proliferation. The proliferation of CD3+CD4+ T cells and
CD3+CD4− T cell subsets was significantly inhibited on day 3
by DsRed-MSC added at a 1:5 ratio. DsRed-MSC inhibited both
syngeneic (C57BL/6 Responders cells) (Figure 1E) as well as
allogeneic responder cells (Balb/c Responder cells) (Figure 1F).
DISTRIBUTION OF RADIOACTIVE LABELED SYNGENEIC MSC
We radio-labeled DsRed-MSC and followed their distribution
after intravenous infusion by tracking the radioactive signal.
One hour after administration of MSC, the majority (60%) of
radioactivity was found in the lungs, while a smaller propor-
tion was found in the liver (Figure 2). After 24 h, the amount of
radioactivity in the lungs was strongly reduced, while the amount
of radioactivity in the liver was increased. A small amount of
radioactivity was found in the spleen. Radioactivity in other
organs was around background levels.
PRESENCE OF LIVING DsRed-MSC IN TISSUE CULTURES
To examine whether infused MSC home to lungs, liver and per-
haps other tissues as living cells, DsRed-MSC (500,000) were
infused via the tail vein in syngeneic C57BL/6 mice and tis-
sues isolated at various time points after infusion and brought
into culture to detect the presence of viable DsRed-MSC. Thus,
after 5min, 1, 24, or 72 h mice were sacrificed and blood, lungs,
liver, spleen, kidneys, and bone marrow collected and cell cul-
tures established in MSC-supporting culture medium. Adherent
cell cultures reaching confluency after 7–10 days were obtained
from lung, spleen, kidney, and bone marrow tissues. The cul-
tures consisted of multiple cell types, including macrophage-like
cells, endothelial cells, and fibroblastic cells. Single colonies of
fibroblastic cells were obtained from blood and liver tissue.
Analysis by fluorescence microscopy revealed that cultures
obtained from blood collected 5min after MSC infusion con-
tained no DsRed-MSC. However, lung tissue cultures con-
tained red fluorescent cells, indicating that living donor MSC
were present in the lungs 5min after infusion of DsRed-MSC.
Interestingly, after 2 days of culturing multiple DsRed-MSC were
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FIGURE 1 | DsRed-MSC are phenotypically and functionally comparable
to wild-type MSC. (A) Fluorescence microscopy of plastic adherent
DsRed-MSC in culture shows bright red fluorescence. (B) Flow cytometric
analysis demonstrates that DsRed-MSC are negative for the expression of
CD34, CD11b, CD11c, and CD117, show weak expression of MHC class I, and
are positive for Sca-1, CD44, and RFP (DsRed). (C) DsRed-MSC are capable of
differentiating into adipocytes, as demonstrated by staining of lipid vesicles by
Oil-Red-O (left), while remaining red fluorescent (right). (D) DsRed-MSC are
capable of differentiating into osteoblasts, indicated by positive silver nitrate
staining for calcium deposits (left), while remaining red fluorescent (right).
(E and F) DsRed-MSC suppress ConA induced proliferation of CD4 positive
and negative T cells efficiently, determined by CFSE dilution on day 3 (solid
line: ConA stimulated T cells, gray shaded curve: ConA stimulated T cells +
MSC, dotted line: non-stimulated T cells). DsRed-MSC suppressed the
proliferation of syngeneic C57BL/6 responder T cells (E) as well as allogeneic
Balb/c responder T cells (F). Representative data of 3 experiments shown.
frequently shown in close proximity, suggesting that the cells were
proliferating (Figure 3A). After 7 days of culture, DsRed-MSC
were mostly found in colonies rather than equally distributed
throughout the cultures (Figure 3B). Flow cytometric analysis
of lung tissue after 7 days of culture confirmed the presence of
DsRed-MSC expressing the MSC marker CD44+ (Figure 3C).
Cultures from spleen, kidney, liver, and bone marrow established
5min after MSC infusion contained no DsRed-MSC.
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FIGURE 2 | Distribution of Cr-51 radioactivity after infusion of Cr-51
labeled DsRed-MSC. (A) One hour after intravenous injection, more than
60% of total radioactivity is located in the lungs and approximately 10%
in the liver. Other tissues contain only residual radioactivity. After 24 h, the
majority of radioactivity is located in the liver. (B) As in (A), but absolute
counts shown. Dashed line indicates background radioactivity. Cervical,
axillary, inguinal, hepatic, para-aortal, and mesenteric lymph nodes were
collected. Average data of 2 experiments is shown.
DsRed-MSC were also present in lung cultures established 1 h
after MSC infusion, but their numbers were strongly reduced in
cultures obtained at 24 h. No DsRed-MSC were detected in lung
cultures established 72 h after MSC infusion, suggesting that the
infused MSC were either no longer viable or had migrated to
other tissues. Surprisingly, living DsRed-MSC were not detected
in cultures of any of the other tissues established at 1, 24, or 72 h
after MSC infusion (Table 1).
PRESENCE OF LIVING DsRed-MSC IN ISCHEMIA-REPERFUSION
INJURY LIVER TISSUE
To examine whether organ injury would provide a trigger for
MSC to migrate to the organ, ischemia-reperfusion injury was
induced in the liver of mice by clamping the hepatic artery, por-
tal vein, and bile duct for 45min in order to prevent about 70%
of the liver lobes from blood supply. One hour before ischemia-
reperfusion injury, 500,000 DsRed-MSC were infused via the tail
vein. At this time point we know from the previously described
experiments that living MSC are present in the lung. Twenty-four
hours after reperfusion, the organs were removed and MSC
brought into culture. No living DsRed-MSC were detected in liver
tissue after ischemia-reperfusion injury (Table 1). DsRed-MSC
were present in lung tissue, like in control animals.
PRESENCE OF LIVING DsRed-MSC IN Rag2−/−× γ-chain−/−
RECIPIENTS
To determine whether NK, T, and B cells were responsible for the
rapid disappearance of living DsRed-MSC after infusion, DsRed-
MSC were infused in Rag2−/− × γ-chain−/− double knock-out
mice that are deficient for these cells, and organs removed and
cultures established. Like in wild-type mice, living DsRed-MSC
were found in lung tissue up to 24 h after infusion, but not in any
other tissue at any time point (results not shown).
DISCUSSION
MSC therapy has shown to be effective as an immunomodula-
tory and regenerative therapy in a number of animal models,
including transplant models (Popp et al., 2008), experimental
colitis (Gonzalez et al., 2009), pancreatitis (Jung et al., 2011),
experimental multiple sclerosis (Fisher-Shoval et al., 2012), and
several others. The mechanisms that mediate the effects of MSC
in these models are not clear. The old dogma that adminis-
tered MSC engraft and differentiate in specialized cell types has
been abandoned, whereas the proposition that the effects of MSC
are mediated via the secretion of trophic and immunoregulatory
factors has gained in popularity.
In the present study we demonstrated that MSC accumulate
in the lungs within the first few hours after intravenous infu-
sion. This is in agreement with earlier findings (Barbash et al.,
2003; Kraitchman et al., 2005; Assis et al., 2010). Importantly,
we were able to demonstrate that at least some of the exogenous
MSC remained viable in the lungs up to 24 h after infusion. Re-
culturing of these MSC demonstrated that they maintained their
proliferation capacity. During the first 24 h after infusion, living
MSC were not found in blood, liver, spleen, kidney, or bone mar-
row. After 24 h, living MSC disappeared from the lungs, but did
not reappear in the other tissues examined, suggesting they did
not survive long term in the recipient animals.
As it has been suggested that MSCmigrate to sites of injury, we
induced ischemia-reperfusion injury in the liver and examined
whether viable administered MSC would appear in the injured
liver. We found, however, no living donor MSC in the injured
liver, indicating there is no difference in the migration of viable
MSC to injured and non-injured organs.
The identification of viable MSC after infusion has not been
demonstrated earlier and shines a new light on the fate of MSC
after administration. Other studies reported the migration of
MSC to various sites, particularly liver and spleen, and to sites
of injury. In our experiments, radioactivity was found in the
liver and spleen 24 h after injection of radio-labeled MSC but we
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FIGURE 3 | Viable MSC are detected in lung tissue only after intravenous
infusion. (A) Brightfield, immunofluorescent, and merged microscopic
images show two DsRed-MSC in a two days-old culture of lung tissue
established 5min after MSC infusion. (B) After 7 days of culture clusters of
DsRed-MSC are seen. (C) Flow cytometric analysis of cultures established
from lung tissue 5min after DsRed-MSC infusion cultured for 7 days revealed
a distinct population of CD44+ DsRed-MSC (middle plot), while in cultures of
PBS treated animals no DsRed-MSC were present (left plot). Mono-cultures
of DsRed-MSC served as gating control (right plot). Five animals were
included per group. Representative data shown.
Table 1 | The presence of living MSC in tissues 5min, 1, 24, and 72h
after infusion of 500,000 DsRed-MSC via the tail vein at T = 0.
T = 0 T = 5min T = 1h T = 24h T = 24h T = 72h
liver IRI*
Blood + − − − − −
Lung − + + + + −
Liver − − − − − −
Spleen − − − − − −
Kidney − − − − − −
Bone marrow − − − − − −
Five animals were included per group.
*Liver IRI: 45min of ischemia-reperfusion injury of the liver, MSC infusion 1 h
before ischemia-reperfusion injury.
failed to isolate viable MSC from these organs. Our data indi-
cate that living MSC do not pass the capillary bed of the lungs
after intravenous infusion. It is therefore likely that previous stud-
ies describing MSC in other tissues detected MSC-label (e.g.,
radioactivity, fluorescence) from MSC debris or from phagocy-
tosed MSC rather than living MSC. Our studies suggest that other
routes of administration have to be investigated if MSC need to be
delivered to tissues other than the lungs. For instance, administra-
tion via the portal vein could be used for delivery of MSC to the
liver, while arterial administration may deliver MSC to specific
organs. The survival of MSC administered via such alternative
routes could be examined by the methods used in the present
paper.
How intravenously administered MSC disappear from the
lungs is not clear at this stage. One possibility could be that MSC
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are damaged by shear forces after infusion. However, the survival
of MSC for up to 24 h in the lungs suggests that their removal is
caused by other mechanisms. Immune cells may well be involved
in this process. In the present study, the administered MSC were
of syngeneic origin, which would suggest a role for cells of the
innate immune system in the removal of MSC. Activated NK cells
have been shown to be capable of lysing autologous MSC in vitro
(Spaggiari et al., 2006; Crop et al., 2011). We, however, demon-
strated that infused MSC do not have an increased life span in
mice that lack NK cells. Other cells of the innate immune sys-
tem, in particular macrophages, may play a more important role.
If the innate immune system is responsible for the loss of admin-
istered MSC, it is questionable whether conventional immuno-
suppressive drugs would be capable of preventing the removal
of MSC, as these drugs mainly target the adaptive immune
system.
Our data clearly demonstrate the short-term survival of
infused MSC and a lack of distribution of viable MSC beyond the
lungs. Nevertheless, several studies have demonstrated beneficial
effects of MSC in a variety of disease models (Gonzalez et al.,
2009; Semedo et al., 2009; Kanazawa et al., 2011) even when
MSC were no longer around (Yang et al., 2012). The ques-
tion now arises how these effects are mediated. It seems clear
that delivery of MSC to a site of injury is not required for
a therapeutic effect. It has been hypothesized that apoptosis
of infused cells can trigger an immunomodulatory response
(Thum et al., 2005) and recently it was demonstrated that
macrophages adapt an immunoregulatory function after phago-
cytosis of dead (MSC) (Lu et al., 2012). Our results sug-
gest this process may happen in the lungs and from there
develop into a response that eventually targets the immune
response at sites of inflammation and injury. Future research
will have to reveal which signals conduct this response through
the body.
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